<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font6" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font7" size="8" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font9" size="8" family="Symbol" color="#000000"/>
<text top="41" left="55" width="208" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>Current Controlled Trials in Cardiovascular Medicine</i></text>
<text top="41" left="263" width="27" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2005, </text>
<text top="41" left="291" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>6</b></text>
<text top="41" left="296" width="13" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:15</text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://cvm.controlled-trials.com/content/6/1/15</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="97" segment_no="16" tag_type="text">Page 7 of 9</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="98" segment_no="17" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="62" segment_no="4" tag_type="text">severe ischemic left ventricular dysfunction or those</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="63" segment_no="4" tag_type="text">undergoing redo-CABG. High-risk patients participating</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="64" segment_no="4" tag_type="text">in previous clopidogrel studies have been found to derive</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="65" segment_no="4" tag_type="text">an enhanced benefit with the combined treatment of</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="66" segment_no="4" tag_type="text">clopidogrel and aspirin <a href="">[42]. Furthe</a>rmore, there is no rea-</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="67" segment_no="4" tag_type="text">son to anticipate differences in the pathophysiology of</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="68" segment_no="4" tag_type="text">vein graft disease between high risk patients and those of</text>
<text top="557" left="55" width="111" height="9" font="font4" id="p1_t15" reading_order_no="69" segment_no="4" tag_type="text">the proposed study group.</text>
<text top="580" left="55" width="56" height="10" font="font5" id="p1_t16" reading_order_no="70" segment_no="8" tag_type="title"><b>Conclusion</b></text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="71" segment_no="10" tag_type="text">Saphenous vein graft disease continues to be a major lim-</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="72" segment_no="10" tag_type="text">itation of surgical revascularization for coronary artery</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="73" segment_no="10" tag_type="text">disease. The process of saphenous vein intimal hyperpla-</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="74" segment_no="10" tag_type="text">sia begins just days after surgery, setting the stage for graft</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="75" segment_no="10" tag_type="text">atherosclerotic disease and its sequalae. Clopidogrel has</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="76" segment_no="10" tag_type="text">been demonstrated to improve outcomes in patients with</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="77" segment_no="10" tag_type="text">coronary and vascular disease, and it is effective at reduc-</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="78" segment_no="10" tag_type="text">ing intimal hyperplasia in animal models of thrombosis.</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="79" segment_no="10" tag_type="text">However, no prospective study to date has been con-</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="80" segment_no="10" tag_type="text">ducted in humans regarding the use of clopidogrel after</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="81" segment_no="10" tag_type="text">CABG to prevent vein graft intimal hyperplasia. The CAS-</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="82" segment_no="10" tag_type="text">CADE trial is a randomized, placebo-controlled trial com-</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t29" reading_order_no="83" segment_no="5" tag_type="text">paring clopidogrel plus aspirin versus aspirin alone in</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t30" reading_order_no="84" segment_no="5" tag_type="text">CABG patients revascularized with saphenous vein. The</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t31" reading_order_no="85" segment_no="5" tag_type="text">effects of clopidogrel on vein graft intimal hyperplasia</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t32" reading_order_no="86" segment_no="5" tag_type="text">will be studied with coronary angiography and intravascu-</text>
<text top="521" left="313" width="172" height="9" font="font4" id="p1_t33" reading_order_no="87" segment_no="5" tag_type="text">lar ultrasound one year following CABG.</text>
<text top="545" left="313" width="70" height="10" font="font5" id="p1_t34" reading_order_no="88" segment_no="6" tag_type="title"><b>Abbreviations</b></text>
<text top="557" left="313" width="185" height="9" font="font4" id="p1_t35" reading_order_no="89" segment_no="7" tag_type="text">CABG – coronary artery bypass graft surgery</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t36" reading_order_no="90" segment_no="9" tag_type="text">CASCADE – Clopidogrel after Surgery for Coronary Artery</text>
<text top="592" left="313" width="53" height="9" font="font4" id="p1_t37" reading_order_no="91" segment_no="9" tag_type="text">Disease Trial</text>
<text top="615" left="313" width="127" height="9" font="font4" id="p1_t38" reading_order_no="92" segment_no="11" tag_type="text">CBC – complete blood counts</text>
<text top="639" left="313" width="134" height="9" font="font4" id="p1_t39" reading_order_no="93" segment_no="12" tag_type="text">IVUS – intravascular ultrasound</text>
<text top="662" left="313" width="113" height="9" font="font4" id="p1_t40" reading_order_no="94" segment_no="13" tag_type="text">MI – myocardial infarction</text>
<text top="686" left="313" width="180" height="9" font="font4" id="p1_t41" reading_order_no="95" segment_no="14" tag_type="text">OHI – University of Ottawa Heart Institute</text>
<text top="709" left="313" width="234" height="9" font="font4" id="p1_t42" reading_order_no="96" segment_no="15" tag_type="text">OPCAB – off-pump coronary artery bypass graft surgery</text>
<text top="87" left="55" width="174" height="7" font="font6" id="p1_t43" reading_order_no="5" segment_no="2" tag_type="title"><b>Table 1: Study Inclusion and Exclusion Criteria</b></text>
<text top="105" left="59" width="64" height="7" font="font7" id="p1_t44" reading_order_no="6" segment_no="3" tag_type="table"><i><b>Inclusion Criteria:</b></i></text>
<text top="105" left="309" width="28" height="7" font="font7" id="p1_t45" reading_order_no="9" segment_no="3" tag_type="table"><i><b>Reason:</b></i></text>
<text top="115" left="59" width="225" height="7" font="font8" id="p1_t46" reading_order_no="7" segment_no="3" tag_type="table">- Patients undergoing primary multi-vessel CABG with at least two </text>
<text top="124" left="59" width="211" height="7" font="font8" id="p1_t47" reading_order_no="8" segment_no="3" tag_type="table">saphenous vein grafts, with or without cardiopulmonary bypass</text>
<text top="115" left="309" width="117" height="7" font="font8" id="p1_t48" reading_order_no="10" segment_no="3" tag_type="table">- The population of clinical interest</text>
<text top="147" left="59" width="115" height="7" font="font7" id="p1_t49" reading_order_no="11" segment_no="3" tag_type="table"><i><b>Preoperative Exclusion Criteria:</b></i></text>
<text top="147" left="309" width="28" height="7" font="font7" id="p1_t50" reading_order_no="29" segment_no="3" tag_type="table"><i><b>Reason:</b></i></text>
<text top="157" left="59" width="69" height="7" font="font8" id="p1_t51" reading_order_no="12" segment_no="3" tag_type="table">- Emergency surgery</text>
<text top="157" left="309" width="90" height="7" font="font8" id="p1_t52" reading_order_no="30" segment_no="3" tag_type="table">- Unable to obtain consent</text>
<text top="167" left="59" width="50" height="7" font="font8" id="p1_t53" reading_order_no="13" segment_no="3" tag_type="table">- Valve surgery</text>
<text top="167" left="309" width="158" height="7" font="font8" id="p1_t54" reading_order_no="31" segment_no="3" tag_type="table">- Requirement of postoperative anticoagulation</text>
<text top="177" left="59" width="47" height="7" font="font8" id="p1_t55" reading_order_no="14" segment_no="3" tag_type="table">- Redo CABG</text>
<text top="177" left="309" width="211" height="7" font="font8" id="p1_t56" reading_order_no="32" segment_no="3" tag_type="table">- Higher risk of postoperative bleeding and low cardiac output </text>
<text top="187" left="309" width="33" height="7" font="font8" id="p1_t57" reading_order_no="33" segment_no="3" tag_type="table">syndrome</text>
<text top="197" left="59" width="127" height="7" font="font8" id="p1_t58" reading_order_no="15" segment_no="3" tag_type="table">- Left ventricle ejection fraction &lt;25%</text>
<text top="197" left="309" width="216" height="7" font="font8" id="p1_t59" reading_order_no="34" segment_no="3" tag_type="table">- Higher risk of postoperative low cardiac output syndrome and </text>
<text top="206" left="309" width="30" height="7" font="font8" id="p1_t60" reading_order_no="35" segment_no="3" tag_type="table">mortality</text>
<text top="216" left="59" width="83" height="7" font="font8" id="p1_t61" reading_order_no="16" segment_no="3" tag_type="table">- Serum creatinine &gt;130 </text>
<text top="214" left="142" width="5" height="11" font="font9" id="p1_t62" reading_order_no="17" segment_no="3" tag_type="table">µ</text>
<text top="216" left="147" width="19" height="7" font="font8" id="p1_t63" reading_order_no="18" segment_no="3" tag_type="table">mol/L</text>
<text top="216" left="309" width="184" height="7" font="font8" id="p1_t64" reading_order_no="36" segment_no="3" tag_type="table">- Contraindication to use of postoperative angiography</text>
<text top="227" left="59" width="229" height="7" font="font8" id="p1_t65" reading_order_no="19" segment_no="3" tag_type="table">- Preoperative use of clopidogrel (with the exception of the current </text>
<text top="236" left="59" width="35" height="7" font="font8" id="p1_t66" reading_order_no="20" segment_no="3" tag_type="table">admission)</text>
<text top="227" left="309" width="199" height="7" font="font8" id="p1_t67" reading_order_no="37" segment_no="3" tag_type="table">- Contraindication to randomization, confounding of results</text>
<text top="246" left="59" width="100" height="7" font="font8" id="p1_t68" reading_order_no="21" segment_no="3" tag_type="table">- Preoperative use of warfarin</text>
<text top="246" left="309" width="158" height="7" font="font8" id="p1_t69" reading_order_no="38" segment_no="3" tag_type="table">- Requirement of postoperative anticoagulation</text>
<text top="256" left="59" width="112" height="7" font="font8" id="p1_t70" reading_order_no="22" segment_no="3" tag_type="table">- Allergy to aspirin or clopidogrel</text>
<text top="256" left="309" width="167" height="7" font="font8" id="p1_t71" reading_order_no="39" segment_no="3" tag_type="table">- Contraindication to use of aspirin or clopidogrel</text>
<text top="267" left="59" width="124" height="7" font="font8" id="p1_t72" reading_order_no="23" segment_no="3" tag_type="table">- History of cerebrovascular accident</text>
<text top="267" left="309" width="131" height="7" font="font8" id="p1_t73" reading_order_no="40" segment_no="3" tag_type="table">- Concurrent indication for clopidogrel</text>
<text top="277" left="59" width="106" height="7" font="font8" id="p1_t74" reading_order_no="24" segment_no="3" tag_type="table">- History of severe liver disease</text>
<text top="277" left="309" width="133" height="7" font="font8" id="p1_t75" reading_order_no="41" segment_no="3" tag_type="table">- Contraindication to use of clopidogrel</text>
<text top="287" left="59" width="56" height="7" font="font8" id="p1_t76" reading_order_no="25" segment_no="3" tag_type="table">- Morbid obesity</text>
<text top="287" left="309" width="158" height="7" font="font8" id="p1_t77" reading_order_no="42" segment_no="3" tag_type="table">- Unable to perform postoperative angiography</text>
<text top="297" left="59" width="126" height="7" font="font8" id="p1_t78" reading_order_no="26" segment_no="3" tag_type="table">- Residence outside of Ottawa region</text>
<text top="297" left="309" width="158" height="7" font="font8" id="p1_t79" reading_order_no="43" segment_no="3" tag_type="table">- Unable to perform postoperative angiography</text>
<text top="308" left="59" width="70" height="7" font="font8" id="p1_t80" reading_order_no="27" segment_no="3" tag_type="table">- Current malignancy</text>
<text top="308" left="309" width="150" height="7" font="font8" id="p1_t81" reading_order_no="44" segment_no="3" tag_type="table">- Higher risk of early postoperative mortality</text>
<text top="318" left="59" width="129" height="7" font="font8" id="p1_t82" reading_order_no="28" segment_no="3" tag_type="table">- Inability to provide informed consent</text>
<text top="318" left="309" width="136" height="7" font="font8" id="p1_t83" reading_order_no="45" segment_no="3" tag_type="table">- Ineligible for research study enrollment</text>
<text top="340" left="59" width="118" height="7" font="font7" id="p1_t84" reading_order_no="46" segment_no="3" tag_type="table"><i><b>Postoperative Exclusion Criteria:</b></i></text>
<text top="340" left="309" width="28" height="7" font="font7" id="p1_t85" reading_order_no="55" segment_no="3" tag_type="table"><i><b>Reason:</b></i></text>
<text top="350" left="59" width="241" height="7" font="font8" id="p1_t86" reading_order_no="47" segment_no="3" tag_type="table">- Low cardiac output syndrome with inotropic support for greater than </text>
<text top="360" left="59" width="30" height="7" font="font8" id="p1_t87" reading_order_no="48" segment_no="3" tag_type="table">24 hours</text>
<text top="350" left="309" width="176" height="7" font="font8" id="p1_t88" reading_order_no="56" segment_no="3" tag_type="table">- Unstable patient unlikely to benefit from treatment</text>
<text top="370" left="59" width="119" height="7" font="font8" id="p1_t89" reading_order_no="49" segment_no="3" tag_type="table">- Recurrent ventricular arrhythmias</text>
<text top="370" left="309" width="176" height="7" font="font8" id="p1_t90" reading_order_no="57" segment_no="3" tag_type="table">- Unstable patient unlikely to benefit from treatment</text>
<text top="380" left="59" width="120" height="7" font="font8" id="p1_t91" reading_order_no="50" segment_no="3" tag_type="table">- Intubation for more than 24 hours</text>
<text top="380" left="309" width="176" height="7" font="font8" id="p1_t92" reading_order_no="58" segment_no="3" tag_type="table">- Unstable patient unlikely to benefit from treatment</text>
<text top="390" left="59" width="218" height="7" font="font8" id="p1_t93" reading_order_no="51" segment_no="3" tag_type="table">- Postoperative bleeding or cardiac tamponade requiring surgical </text>
<text top="400" left="59" width="39" height="7" font="font8" id="p1_t94" reading_order_no="52" segment_no="3" tag_type="table">exploration</text>
<text top="390" left="309" width="133" height="7" font="font8" id="p1_t95" reading_order_no="59" segment_no="3" tag_type="table">- Contraindication to use of clopidogrel</text>
<text top="410" left="59" width="134" height="7" font="font8" id="p1_t96" reading_order_no="53" segment_no="3" tag_type="table">- Postoperative gastrointestinal bleeding</text>
<text top="410" left="309" width="133" height="7" font="font8" id="p1_t97" reading_order_no="60" segment_no="3" tag_type="table">- Contraindication to use of clopidogrel</text>
<text top="420" left="59" width="125" height="7" font="font8" id="p1_t98" reading_order_no="54" segment_no="3" tag_type="table">- Postoperative warfarin requirement</text>
<text top="420" left="309" width="133" height="7" font="font8" id="p1_t99" reading_order_no="61" segment_no="3" tag_type="table">- Contraindication to use of clopidogrel</text>
</page>
</pdf2xml>
